Affymax (AFFY +4.9%) gains after announcing the FDA will review the company's application for...


Affymax (AFFY +4.9%) gains after announcing the FDA will review the company's application for its Peginesatide drug, which treats anemia in patients with chronic kidney disease, on December 7, and has established an "action date" for the application of March 27.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs